Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.

Clinical epigenetics - 3 Jan 2025

Tang Yu, Zhang Ruizhi, Mao Gan, Li Chong, Gao Yisong, Zhou Xuebing, Nie Wenxiang, Song Tianyu, Liu Suao, Tao Kaixiong, Zhang Peng, Li Wei

Abstract excerpt

BACKGROUND: The primary objective of this study was to examine whether ARID1A mutations confer a fitness advantage to gastric cancer from an immunological perspective, along with elucidating the underlying mechanism. Additionally, we aimed to identify the clinical potential of combining epigenetic inhibitors with immune checkpoint inhibitors to improve the efficacy of immunotherapy for gastric cancer. METHODS:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokine CXCL10

Share to Histone Deacetylase Inhibitors

Share to Histones

Share to Immune Checkpoint Inhibitors

Share to Immunotherapy

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39754248
DOI: 10.1186/s13148-024-01805-9
PMCID: PMC11697466

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impaired ARID1A expression attenuated the immune response in gastric cancer via histone acetylation.PMID 39754248Read ↗

ARID1A is a coactivator of STAT5 that contributes to CD8+ T cell dysfunction and anti-PD-1 resistance in gastric cancer.Semantic proximity Read ↗

Comprehensive molecular phenotyping of ARID1A-deficient gastric cancer reveals pervasive epigenomic reprogramming and therapeutic opportunities.Semantic proximity Read ↗

The effects of ARID1A mutation in gastric cancer and its significance for treatmentSemantic proximity Read ↗

Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective studySemantic proximity Read ↗

Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy.Semantic proximity Read ↗

Clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.Semantic proximity Read ↗

ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal CancerSemantic proximity Read ↗

Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studiesSemantic proximity Read ↗

Loss of ARID1A Expression is Associated with Systemic Inflammation Markers and has Important Prognostic Significance in Gastric Cancer.Semantic proximity Read ↗

Loss of ARID1A Expression is Related to Gastric Cancer Progression, Epstein-Barr Virus Infection, and Mismatch Repair DeficiencySemantic proximity Read ↗

Epigenetic driver mutations in ARID1A shape cancer immune phenotype and immunotherapy.Semantic proximity Read ↗

Tumor context determines <i>ARID1A</i> effects on gastric cancer immunitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.